Table 1. Patient characteristics.

	N
Male/Female	4/26
Age, median (range)	76 (38–97)
EGFR-TKI Gefitinib/Erlotinib	29/1
Relapse site brain/pleural effusion/bone/lung	5/13/6/8
ECOG PS on PD 0/1/2/3/4	2/16/6/5/1
Sequential therapy second-line/beyond PD/BSC	8/12/10
Second-line therapy (n = 10) doublet/mono	6/2

Abbreviations: EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; ECOG, Eastern Cooperative Oncology Group; PS, performance status; PD, progressive disease; BSC, best supportive care